All In Biotech

BLA 761379 · Fresenius Kabi USA

Otulfi

Ustekinumab-Aauz · Injection · Interleukin-12 Antagonist; Interleukin-23 Antagonist

Last checked: Nov 20, 2026Latest source record: Jan 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Apr 30, 2025

Approved uses

2

Original approval plus efficacy supplements

Registered trials

164

71 Phase 3, 28 recruiting

FAERS reports

17

11 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 14, 2026.

OTULFI is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: • moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. ( 1.1 ) • active psoriatic arthritis (PsA) . ( 1.2 ) • moderately to severely active Crohn's disease (CD) . ( 1.3 ) • moderately to severely active ulcerative colitis. ( 1.4 ) Pediatric patients 6 years and older with: • moderate to severe plaque psoriasis (PsO) , who are candidates for phototherapy or systemic therapy. ( 1.1 ) • active psoriatic arthritis (PsA) . ( 1.2 ) 1.1 Plaque Psoriasis (PsO) OTULFI is indicated for the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. 1.2 Psoriatic Arthritis (PsA) OTULFI is indicated for the treatment of adults and pediatric patients 6 years of age and older with active psoriatic arthritis. 1.3 Crohn's Disease (CD) OTULFI is indicated for the treatment of adult patients with moderately to severely active Crohn's disease. 1.4 Ulcerative Colitis OTULFI is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.

Mechanism: Ustekinumab products are human IgG1қ monoclonal antibodies that bind with specificity to the p40 protein subunit used by both the IL-12 and IL-23 cytokines. IL-12 and IL-23 are naturally occurring cytokines that are involved in inflammatory and immune responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation. In in vitro models, ustekinumab products were shown to disrupt IL-12 and IL-23 mediated signaling and cytokine cascades by disrupting the interaction of these cytokines with a shared cell-surface receptor chain, IL-12Rβ1. The cytokines IL-12 and...

Therapeutic areas: Immunology and inflammation

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

3 products under this application
  • OTULFI · USTEKINUMAB-AAUZ 90MG/1ML · INJECTABLE, INJECTION · Prescription
  • OTULFI · USTEKINUMAB-AAUZ 130MG/26ML · INJECTABLE, INJECTION · Prescription
  • OTULFI · USTEKINUMAB-AAUZ 45MG/0.5ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Ustekinumab" as an intervention, any sponsor and status, largest first.

All 164 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • pain3
  • accidental exposure to product2
  • anxiety2
  • death2
  • drug ineffective2
  • eosinophilic oesophagitis2
  • exposure via skin contact2
  • fatigue2
  • product use in unapproved indication2
  • treatment failure2
  • abdominal discomfort1
  • acute kidney injury1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20256
202611

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 577 on PubMed

Sponsor: Fresenius Kabi USA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.